cas 3970-21-6|| where to buy 2-Methoxyethoxymethyl chloride

Produktname:2-Methoxyethoxymethyl chloride

IUPAC Name:1-(chloromethoxy)-2-methoxyethane

Packungseinheit	Verfügbarer Vorrat	Preis($)	Menge
CM342464-500g	in stock	ȌǠƤ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 3970-21-6 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:3970-21-6; Molekulare Formel:C4H9ClO2; Schmelzpunkt:-; SMILES-Code:COCCOCCl; Dichte:

: Katalognummer:CM342464; Molekulargewicht:124.56; Siedepunkt:; Mdl-Nr.:MFCD00000888; Lagerung:

: Aliphatic Chain Compounds; Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

: ABBV-CLS-484; Nature publishes discovery and preclinical results for ABBV-CLS-484, a potential first-in-class PTPN2/N1 inhibitor in cancer immunotherapy.
ABBV-CLS-484 is the first active-site phosphatase inhibitor to enter clinical evaluation as a cancer therapy and is currently in an AbbVie and Calico-led Phase 1 clinical trial in solid tumors.